Pharmacokinetic, bioequivalence, and safety assessments of two brands of 30-mg nifedipine controlled-release formulations in Chinese healthy subjects
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204605 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Huan Lu und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Calcium Channel Blockers, Delayed-Action Preparations, Nifedipine, Postprandial Period.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Lu, H., Zhou, F., Rui, C., You, H., Zhang, W., Zhang, Y., Ding, J., Zhao, S., & Wu, Q. (2024). Pharmacokinetic, bioequivalence, and safety assessments of two brands of 30-mg nifedipine controlled-release formulations in Chinese healthy subjects. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204605
Vancouver
Lu H, Zhou F, Rui C, You H, Zhang W, Zhang Y, et al. Pharmacokinetic, bioequivalence, and safety assessments of two brands of 30-mg nifedipine controlled-release formulations in Chinese healthy subjects. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204605
BibTeX
@article{Lu2024,
author = {Lu, Huan and Zhou, Fei and Rui, Cuijie and You, Hen and Zhang, Wenhao and Zhang, Yaxin and Ding, Juefang and Zhao, Shunbo and Wu, Qiang},
title = {Pharmacokinetic, bioequivalence, and safety assessments of two brands of 30-mg nifedipine controlled-release formulations in Chinese healthy subjects},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204605}
}
EUVIMED